Crossmark

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

Crossref DOI link: https://doi.org/10.1038/nbt.3179

Published Online: 2015-03-23

Published Print: 2015-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mailly, Laurent https://orcid.org/0000-0001-6957-7463
Xiao, Fei

Lupberger, Joachim

Wilson, Garrick K

Aubert, Philippe

Duong, François H T

Calabrese, Diego

Leboeuf, Céline

Fofana, Isabel

Thumann, Christine

Bandiera, Simonetta

Lütgehetmann, Marc

Volz, Tassilo

Davis, Christopher

Harris, Helen J

Mee, Christopher J

Girardi, Erika

Chane-Woon-Ming, Béatrice

Ericsson, Maria

Fletcher, Nicola

Bartenschlager, Ralf

Pessaux, Patrick

Vercauteren, Koen

Meuleman, Philip

Villa, Pascal

Kaderali, Lars

Pfeffer, Sébastien https://orcid.org/0000-0002-8458-348X
Heim, Markus H https://orcid.org/0000-0002-7523-4894
Neunlist, Michel

Zeisel, Mirjam B

Dandri, Maura

McKeating, Jane A

Robinet, Eric

Baumert, Thomas F
License Information

Text and Data Mining valid from 2015-03-23
More Information

Article History

Received: 1 October 2014

Accepted: 22 December 2014

First Online: 23 March 2015

Competing interests

: Inserm, the University of Strasbourg and Genovac/Aldevron Freiburg have filed a patent application on monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection (US Patent # 8,518,408; WO2010034812; PCT/EP2009/062449). T.F.B. has served as a scientific advisor for Gilead, Biotest and Vironexx.